UK to offer new vaccine shots to Novavax trial volunteers
Britain says it it will offer new vaccinations to thousands of people who volunteered for trials of the Novavax coronavirus vaccine, which has not yet been approved for use in any country
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Britain announced Friday that it will offer new vaccinations to thousands of people who volunteered for trials of the Novavax coronavirus vaccine, which hasn't yet been approved for use in any country.
Around 15,000 people in the U.K. got Novavax shots as part of a clinical trial. While the U.K. recognizes them as vaccinated, most countries don’t, meaning they can’t travel.
Britain’s health department said more than 15,000 participants will be given two doses of the Pfizer BioNTech vaccine. The government says it plans to expand the offer to about 6,000 U.K. participants in trials of other vaccines that also haven't been approved for use.
Britain has appealed to other members of the Group of 20 nations to classify clinical trial volunteers as vaccinated, but most haven't done so.
England’s deputy chief medical officer, Jonathan Van-Tam noted that “if more countries around the world had reciprocated by allowing U.K. volunteers to enjoy fully vaccinated status for overseas travel, these measures would not have been necessary.”
In June, Novavax announced that its vaccine had proved about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the U.S. and Mexico.
U.S.-based Novavax has asked the World Health Organization to approve its COVID-19 vaccine for emergency use so it can be part of the COVAX global vaccine program. But it has delayed seeking approval in Europe or the United States.
The Novavax shots are easier to store and transport than some other options, and have long been expected to play an important role in increasing supplies in poor countries desperate for more vaccine doses.
___
Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.